Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
Suite of proprietary collagen-binding peptides derived from bone sialoprotein (BSP) that are effective in promoting bone repair and regeneration. More
Identification and use of RAR antagonists to induce bone and cartilage formation More
HU-308, a synthetic cannabinoid has demonstrated in vivo anti-osteoporotic efficacy of agonist highly specific for CB2 that concomitantly restrains bone resorption and stimulates bone formation. HU-308 has no psychotropic or anti-annorexigenic... More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us